CompletedPhase 2NCT00668070

A Proof-of-principle Study of Oral Treatment of Non-alcoholic Steatohepatitis With a Novel PDE4 Inhibitor ASP9831

Studying NON RARE IN EUROPE: Non-alcoholic fatty liver disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Astellas Pharma Inc
Principal Investigator
Use central contact
Astellas Pharma Europe B.V.
Intervention
ASP9831(drug)
Enrollment
114 enrolled
Eligibility
18 years · All sexes
Timeline
20082010

Study locations (27)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00668070 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Non-alcoholic fatty liver disease

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Non-alcoholic fatty liver disease

← Back to all trials